Document ID: chunk:federal_register_of_legislation:F2024C00658:reg:9:p2
Version: federal_register_of_legislation:F2024C00658
Segment Type: reg
Provision Reference: reg 9 (pt 2/7)
Character Range: 9759–13597

penetrating arteries that arise from the vertebral artery, the basilar artery, the middle cerebral artery stem, and the arteries of the circle of Willis;
            (b)          cerebral amyloid angiopathy;
            (c)          cerebral arteriolosclerosis;
            (d)          cerebral venous thrombosis;
            (e)          Moyamoya disease or Moyamoya syndrome;
            (f)           Susac syndrome (retinocochleocerebral vasculopathy); or
            (g)          Sneddon syndrome;
(13)      having thrombotic thrombocytopaenic purpura, sickle cell disorder or vaccine-induced thrombotic thrombocytopaenia at the time of clinical onset;
(14)      being pregnant within the 6 weeks before clinical onset;
(15)      using one or more of the following drugs within the 72 hours before clinical onset:
            (a)          amphetamines and amphetamine-type substances, excluding methylphenidate;
            (b)          cocaine;
            (c)          opioids, including heroin;
            (d)          marijuana;
(16)      taking a non-topical, non-steroidal, anti-inflammatory drug, excluding aspirin, for a continuous period of at least 30 days before clinical onset, where the last dose of the drug was taken within the 7 days before clinical onset;
Note: non-steroidal, anti-inflammatory drug is defined in the Schedule 1 - Dictionary.
(17)      having heat stroke at the time of clinical onset;
Note: heat stroke is defined in the Schedule 1 - Dictionary.
(18)      being envenomated by a snake, scorpion, box jellyfish, bee, hornet or wasp within the 5 days before clinical onset;
(19)      having active migraine at the time of clinical onset;
Note: active migraine is defined in the Schedule 1 - Dictionary.
(20)      having diabetes mellitus at the time of clinical onset;
(21)      having one of the following cardiac conditions with potential to give rise to a cerebral embolus within the 4 four weeks before clinical onset:
            (a)          a prosthetic mitral or aortic valve;
            (b)          acute myocardial infarction;
            (c)          atrial fibrillation and atrial flutter;
            (d)          atrial septal aneurysm;
            (e)          calcification of the mitral or aortic valve;
            (f)           cardiac hydatid cysts;
            (g)          cardiomyopathy;
            (h)          congestive cardiac failure;
            (i)            endocarditis;
            (j)            ischaemic, valvular, arrhythmogenic and hypertensive cardiomyopathy;
            (k)          Lambl's excrescences of the mitral or aortic valve;
            (l)            left atrial aneurysm or dilatation;
            (m)        left ventricular aneurysm;
            (n)          left ventricular dyskinesia;
            (o)          mitral valve prolapse;
            (p)          primary or secondary cardiac tumours;
            (q)          regurgitation of the mitral or aortic valve;
            (r)           rheumatic heart disease;
            (s)           sick sinus syndrome;
            (t)            stenosis of the mitral or aortic valve;
            (u)          thrombus within the left atrium or left ventricle; or
            (v)          valvulitis of the mitral or aortic valve;
(22)      having one of the following non-cardiac causes of cerebral arterial embolism at the time of clinical onset;
(a)          aortic arch atherosclerosis;
(b)          decompression sickness;
(c)          endoscopic retrograde cholangiopancreatography;
(d)          pulmonary barotrauma;
(e)          severe bone trauma;
(f)           thrombus formation within the pulmonary vein, or arteries supplying the affected area of the brain;
(23)      having a deep vein thrombosis or venous air embolism with one of the following anatomical defects at the time